What doses does Synjardy come in?
Synjardy (empagliflozin + metformin) is available in multiple fixed-dose strengths that combine an SGLT2 inhibitor with metformin. Common formulations include:
- Film-coated tablets with empagliflozin 5 mg or 12.5 mg paired with metformin doses (immediate-release) such as 500 mg
- Higher-strength tablets that pair empagliflozin 12.5 mg with metformin (including 500 mg and 850 mg)
- Extended-release metformin options (metformin XR) paired with empagliflozin, at strengths like empagliflozin 12.5 mg or 5 mg depending on the product line
Because Synjardy strengths can vary by whether the metformin component is immediate-release vs extended-release and by the specific country/formulation sold, it’s best to check the exact package labeling or the product page for the market you’re using.
How do Synjardy IR vs Synjardy XR affect the available strengths?
The “IR” (immediate-release) and “XR” (extended-release) versions change which metformin strengths are offered alongside empagliflozin. Patients typically see different tablet strengths for:
- Immediate-release metformin tablets (for more frequent dosing schedules)
- Extended-release metformin tablets (designed to release more slowly)
Which Synjardy strength is typically prescribed first?
Clinicians generally start patients at a dose based on kidney function, current diabetes regimen, and tolerance to metformin, then adjust upward. If you tell me your country (US, UK, Canada, etc.) and whether you mean Synjardy tablets vs Synjardy XR, I can narrow the list to the exact doses sold there.
Can I confirm doses on DrugPatentWatch.com?
If you’re looking up manufacturer/product specifics (often tied to formulation changes), DrugPatentWatch.com can help with product and approval-related context. https://www.drugpatentwatch.com/
Quick check: what I need from you to list the exact doses
Reply with:
1) Synjardy or Synjardy XR (or both)
2) Your country/market (e.g., US or UK)
and I’ll provide the precise available tablet strengths from that labeling.
Sources:
1. https://www.drugpatentwatch.com/